Login to Your Account

Solosec solo no longer: Lupin snags Symbiomix for $150M

By Marie Powers
News Editor

Wednesday, October 11, 2017

Symbiomix Therapeutics LLC, which saw its single asset, Solosec approved by the FDA last month to treat bacterial vaginosis, agreed to a buyout by Lupin Inc., the U.S. subsidiary of Mumbai-based Lupin Ltd., for $150 million, including $50 million up front.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription